356 related articles for article (PubMed ID: 21925000)
1. Rituximab and its use in autoimmune bullous disorders.
Daniel BS; Murrell DF; Joly P
Dermatol Clin; 2011 Oct; 29(4):571-5. PubMed ID: 21925000
[TBL] [Abstract][Full Text] [Related]
2. Rituximab and its use in autoimmune bullous disorders.
Daniel BS; Murrell DF; Joly P
Immunol Allergy Clin North Am; 2012 May; 32(2):331-7, viii. PubMed ID: 22560146
[TBL] [Abstract][Full Text] [Related]
3. [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
Mani LY; Vogt B; Burnier M; Golshayan D
Rev Med Suisse; 2011 Apr; 7(290):819-24. PubMed ID: 21595313
[TBL] [Abstract][Full Text] [Related]
4. Rituximab for autoimmune blistering diseases: recent studies, new insights.
Lunardon L; Payne AS
G Ital Dermatol Venereol; 2012 Jun; 147(3):269-76. PubMed ID: 22648328
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in refractory autoimmune bullous diseases.
Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
[TBL] [Abstract][Full Text] [Related]
6. Rituximab: a B-cell depletion therapy for dermatologic disease.
Prajapati V; Mydlarski PR
Skin Therapy Lett; 2007; 12(6):6-9. PubMed ID: 17762903
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in the treatment of bullous systemic lupus erythematosus.
Alsanafi S; Kovarik C; Mermelstein AL; Werth VP
J Clin Rheumatol; 2011 Apr; 17(3):142-4. PubMed ID: 21441817
[TBL] [Abstract][Full Text] [Related]
8. Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease.
Li Y; Foshee JB; Sontheimer RD
J Am Acad Dermatol; 2011 Apr; 64(4):773-8. PubMed ID: 20494477
[TBL] [Abstract][Full Text] [Related]
9. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases.
Hertl M; Zillikens D; Borradori L; Bruckner-Tuderman L; Burckhard H; Eming R; Engert A; Goebeler M; Hofmann S; Hunzelmann N; Karlhofer F; Kautz O; Lippert U; Niedermeier A; Nitschke M; Pfütze M; Reiser M; Rose C; Schmidt E; Shimanovich I; Sticherling M; Wolff-Franke S
J Dtsch Dermatol Ges; 2008 May; 6(5):366-73. PubMed ID: 18201220
[TBL] [Abstract][Full Text] [Related]
10. Treatment of treatment-resistant autoimmune blistering skin disorders with rituximab.
Jensen AØ; Møller BK; Vangkilde A; Mark B; Obitz ER; Kragballe K; Iversen L
Br J Dermatol; 2009 Jun; 160(6):1359-61. PubMed ID: 19416252
[No Abstract] [Full Text] [Related]
11. Low-dose rituximab is effective in pemphigus.
Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF
Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.
Dierickx D; Delannoy A; Saja K; Verhoef G; Provan D
Am J Hematol; 2011 Mar; 86(3):278-91. PubMed ID: 21328427
[TBL] [Abstract][Full Text] [Related]
13. Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.
Shetty S; Ahmed AR
Autoimmunity; 2013 Dec; 46(8):487-96. PubMed ID: 24151854
[TBL] [Abstract][Full Text] [Related]
14. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
Stübgen JP
J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
[TBL] [Abstract][Full Text] [Related]
15. [Off-label use of biological therapies in systemic diseases].
Hachulla E
Rev Med Interne; 2010 Dec; 31 Suppl 3():S307-14. PubMed ID: 21036424
[No Abstract] [Full Text] [Related]
16. An antibody treats almost all refractory autoimmune diseases: fact and beyond.
Lin LY; Hsu MH; Yang KD
J Formos Med Assoc; 2012 Apr; 111(4):181-2. PubMed ID: 22655322
[No Abstract] [Full Text] [Related]
17. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP
J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
[TBL] [Abstract][Full Text] [Related]
18. [Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases].
Kasperkiewicz M; Zillikens D
Hautarzt; 2007 Feb; 58(2):115-6, 118-21. PubMed ID: 17237928
[TBL] [Abstract][Full Text] [Related]
19. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
[TBL] [Abstract][Full Text] [Related]
20. Bullous Diseases.
Corbaux C; Joly P
Curr Probl Dermatol; 2018; 53():64-69. PubMed ID: 29131038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
